STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer ; volume:15 ; number:1 ; day:4 ; month:7 ; year:2015 ; pages:1-13 ; date:12.2015
BMC cancer ; 15, Heft 1 (4.7.2015), 1-13, 12.2015

Creator: Chibaudel, Benoist

Contributor: Bonnetain, Franck
Tournigand, Christophe
de Larauze, Marine Hug
de Gramont, Armand
Laurent-Puig, Pierre
Paget, Jérôme
Hadengue, Alexandra
Notelet, Dominique
Benetkiewicz, Magdalena
André, Thierry
de Gramont, Aimery
SpringerLink (Online service)

DOI: 10.1186/s12885-015-1503-7

URN: urn:nbn:de:1111-2016110613119

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 24.08.2025, 11:12 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Chibaudel, Benoist
Bonnetain, Franck
Tournigand, Christophe
de Larauze, Marine Hug
de Gramont, Armand
Laurent-Puig, Pierre
Paget, Jérôme
Hadengue, Alexandra
Notelet, Dominique
Benetkiewicz, Magdalena
André, Thierry
de Gramont, Aimery
SpringerLink (Online service)

Other Objects (12)

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

Controversies in the treatment of RAS wild-type metastatic colorectal cancer

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

The relationship between oncogenic KRas and wild-type Ras activity and signaling

Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study

IGF-1 in autosomal dominant cerebellar ataxia - open-label trial

Effects of practicing yoga on alexisomia: an open-label trial

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP

Proteomic characterisation of mutant RAS signalling and oncogene-cooperating activity of wild-type p53

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

Controversies in the treatment of RAS wild-type metastatic colorectal cancer

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

The relationship between oncogenic KRas and wild-type Ras activity and signaling

Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study

IGF-1 in autosomal dominant cerebellar ataxia - open-label trial

Effects of practicing yoga on alexisomia: an open-label trial

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP

Proteomic characterisation of mutant RAS signalling and oncogene-cooperating activity of wild-type p53

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

Controversies in the treatment of RAS wild-type metastatic colorectal cancer

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

The relationship between oncogenic KRas and wild-type Ras activity and signaling

Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study

IGF-1 in autosomal dominant cerebellar ataxia - open-label trial

Effects of practicing yoga on alexisomia: an open-label trial

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP

Proteomic characterisation of mutant RAS signalling and oncogene-cooperating activity of wild-type p53

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

Controversies in the treatment of RAS wild-type metastatic colorectal cancer

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

The relationship between oncogenic KRas and wild-type Ras activity and signaling

Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study

IGF-1 in autosomal dominant cerebellar ataxia - open-label trial

Effects of practicing yoga on alexisomia: an open-label trial

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP

Proteomic characterisation of mutant RAS signalling and oncogene-cooperating activity of wild-type p53

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

Controversies in the treatment of RAS wild-type metastatic colorectal cancer

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

The relationship between oncogenic KRas and wild-type Ras activity and signaling

Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study

IGF-1 in autosomal dominant cerebellar ataxia - open-label trial

Effects of practicing yoga on alexisomia: an open-label trial

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP

Proteomic characterisation of mutant RAS signalling and oncogene-cooperating activity of wild-type p53

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

Controversies in the treatment of RAS wild-type metastatic colorectal cancer

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

The relationship between oncogenic KRas and wild-type Ras activity and signaling

Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study

IGF-1 in autosomal dominant cerebellar ataxia - open-label trial

Effects of practicing yoga on alexisomia: an open-label trial

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP

Proteomic characterisation of mutant RAS signalling and oncogene-cooperating activity of wild-type p53

Related objects

Reset password